Jonathan Q. Tran

In Vitro Antiviral Activity and Single-Dose Pharmacokinetics in Humans of a Novel, Orally Bioavailable Inhibitor of Human Rhinovirus 3C Protease

Amy K. Patick, Mary A. Brothers, Fausto Maldonado et al. · Antimicrobial Agents and Chemotherapy · 2005 · 135 citations

Medicine, Pharmacokinetics, Pharmacology +17

Randomized phase I trials of the safety/tolerability of anti-LINGO-1 monoclonal antibody BIIB033

Jonathan Q. Tran, Jitesh Rana, Frederik Barkhof et al. · Neurology Neuroimmunology & Neuroinflammation · 2014 · 124 citations · Full text

Pharmacy, Neurology, Pharmacology +14

Results From the First‐in‐Human Study With Ozanimod, a Novel, Selective Sphingosine‐1‐Phosphate Receptor Modulator

Jonathan Q. Tran, Jeffrey Hartung, Robert Peach et al. · The Journal of Clinical Pharmacology · 2017 · 111 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +15

Morning spot and 24-hour urinary 6 beta-hydroxycortisol to cortisol ratios: intraindividual variability and correlation under basal conditions and conditions of CYP 3A4 induction.

Jonathan Q. Tran, Steven J. Kovacs, Thomas McIntosh et al. · PubMed · 1999 · 78 citations

Pharmacy, Pharmacokinetics, Pharmacology +13

Absorption, Metabolism, and Excretion, In Vitro Pharmacology, and Clinical Pharmacokinetics of Ozanimod, a Novel Sphingosine 1-Phosphate Receptor Modulator

Sekhar Surapaneni, Usha Yerramilli, April Bai et al. · Drug Metabolism and Disposition · 2021 · 72 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +8